From the Frontline of COVID-19: Parenteral Anticoagulation in Patients that are Obese

Anticoagulants are moving to the frontline in some patients with COVID-19 as emerging data shows pro-thrombotic complications occurring. Many of these agents are weight based and require lab monitoring for efficacy and safety. Unfortunately, obesity is an ongoing epidemic in the US as well and potentially worse outcomes in those with COVID-19. It is imperative that pharmacists have an understanding on how the pharmacokinetics can be altered in patients that are obese or large body weight, along with the recommended dosing weight to use.

The information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.